Acorda Therapeutics, Inc.
ACOR
Rang in aandelen
#39149
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Aandeelprijs
$0.879
Laatst gesynchroniseerd: 2024-05-07
Marktkapitalisatie
$582.38K
Verandering (1 dag)
9.88%
Verandering (1 jaar)
8,690.00%
Land
US
Handel Acorda Therapeutics, Inc. (ACOR)
Categorie
Healthcare
Omzet van Acorda Therapeutics, Inc. (ACOR)
Omzet in Mar 2024 TTM: $115.66M
Volgens de laatste financiële rapporten van Acorda Therapeutics, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $115.66M. In 2022 behaalde het bedrijf een omzet van $118.57M een daling ten opzichte van de omzet in het jaar 2021, die $129.07M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Acorda Therapeutics, Inc. van 2016 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $115.66M | -1.67% |
| 2023 | $117.63M | -0.79% |
| 2022 | $118.57M | -8.14% |
| 2021 | $129.07M | -15.62% |
| 2020 | $152.97M | -20.50% |
| 2019 | $192.41M | -59.19% |
| 2018 | $471.43M | -19.86% |
| 2017 | $588.29M | 13.22% |
| 2016 | $519.60M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 5,616.26% |
IN
|
